Abstracts tagged "pathogenesis and transcriptional regulation"

Abstract Number: 2018 • 2018 ACR/ARHP Annual Meeting
Microenvironment Driven Re-Shaping of Pathogenic T Effector and Regulatory Subset in Active Juvenile Idiopathic Arthritic Patients
Jing Yao Leong¹, Pavanish Kumar¹, Phyllis Chen², Joo Guan Yeo^2,3, Camillus Chua², Sharifah Nur Hazirah², Suzan Saidin¹, Thaschawee Arkachaisri^2,3, Alessandro Consolaro⁴, Marco Gattorno⁵, Alberto Martini⁶ and Salvatore Albani², ¹Translational Immunology Institute, Singhealth/Duke-NUS Academic Medical Centre, Singapore, Singapore, ²Translational Immunology Institute, Singhealth/Duke-NUS Academic Medical Centre, Singapore Health Services Pte Ltd, Singapore, Singapore, ³KK Women's and Children's Hospital, Singapore, Singapore, ⁴Second Paediatric Division, University of Genoa and G Gaslini Institute, Genova, Italy, Genova, Italy, ⁵Second Paediatric Division, University of Genoa and G Gaslini Institute, Genova, Italy, Genoa, Italy, ⁶Pediatric Rheumatology International Trial Organization (PRINTO) Coordinating Centre, Genoa, Italy
Background/Purpose: We have previously identified two CD4 pathogenic circulatory subsets in both T effector (CPLs) and T regulatory (iaTreg) compartments that are both HLA-DR+, antigen…
Abstract Number: 1950 • 2015 ACR/ARHP Annual Meeting
Methylation-Dependent Interference of Two Promoters for the Treg-Specific Protein, Garp, Contributes to Altered Treg Function in Rheumatoid Arthritis
Viktoria Soentgerath¹, Sonja Haupt², Jan Leipe³, Hendrik Schulze-Koops¹ and Alla Skapenko¹, ¹Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany, ²Division of Rheumatology and Clinical Immunology, Med.Klinik und Poliklinik IV, University of Munich, Munich, Germany, ³Division of Rheumatology, University of Munich, Munich, Germany
Background/Purpose: Recently, genome-wide studies identified several Treg-specific genes containing hypomethylated regions that are critical for their expression, so called Treg-specific demethylated regions (TSDR). For example,…
Abstract Number: 2455 • 2014 ACR/ARHP Annual Meeting
IL-6 Proximal Promoter SNP rs18000795 Genotype Strongly Correlates with Synovial Fibroblast IL-6 Expression
Erika Noss¹, Sook Kyung Chang², Gerald Watts² and Michael Brenner², ¹Divison of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose Interleukin (IL)-6 is an important driver of rheumatoid arthritis (RA) pathology, and synovial fibroblasts are a major source of IL-6 in the RA synovium. …
Abstract Number: 2770 • 2013 ACR/ARHP Annual Meeting
Complex Functional Effects Within The HLA Contribute To Sjögren’s Syndrome Pathogenesis and May Influence Both Transcriptional Regulation and Peptide Binding
Christopher J. Lessard^1,2, He Li¹, Indra Adrianto¹, John A. Ice¹, Mikhail G. Dozmorov³, Roland Jonsson⁴, Maureen Rischmueller⁵, Gunnel Nordmark⁶, Xavier Mariette⁷, Corinne Miceli-Richard⁸, Marie Wahren-Herlenius⁹, Torsten Witte¹⁰, Michael T. Brennan¹¹, Roald Omdal¹², Lars Rönnblom¹³, Patrick M. Gaffney¹, Wan-Fai Ng¹⁴, Nelson L. Rhodus¹⁵, Barbara M. Segal¹⁶, Jonathan D. Wren¹, R. Hal Scofield^1,17,18, Juan-Manuel Anaya¹⁹, John B. Harley^20,21, Courtney G. Montgomery¹ and Kathy L. Sivils^1,2, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Arthritis and Clincial Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway, ⁵Rheumatology Department, Queen Elizabeth Hospital, Adelaide, Australia, ⁶Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ⁷Paris-Sud University, Paris, France, ⁸Rheumatology, Université Paris Sud, Le Kremlin Bicêtre, France, ⁹Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ¹⁰Clinical Immunology and Rheumatology, Medical University Hannover, Hanover, Germany, ¹¹Nidcr NIH, Carolinas Medical Center, Charlotte, NC, ¹²Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ¹³Department of Medical Science, Uppsala University, Uppsala, Sweden, ¹⁴Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle upon Tyne, United Kingdom, ¹⁵University of Minnesota, Minneapolis, MN, ¹⁶Rheumatology, Hennepin County Medical Center, Minneapolis, MN, ¹⁷Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁸US Department of Veterans Affairs Medical Center, Oklahoma City, OK, ¹⁹School of Medicine and Health Sciences, Universidad del Rosario. Center for Autoimmune Diseases Research (CREA), Bogotá, Colombia, ²⁰Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²¹US Department of Veterans Affairs Medical Center, Cincinnati, OH
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a common, heterogeneous exocrinopathy. Etiology involves complex environmental, genetic and genomic influences driving innate and adaptive autoimmune responses. This…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].